InVitria to Present at BIO 2009 International Convention in AtlantaInVitria to profile "New Strategies for Optimizing CHO Performance" inside the BIO Process Product Zone on May 20, 2009 in Atlanta, GA.
InVitria's products will also be showcased in the BioProcess Theater, a site located on the exhibition floor and sponsored by BioProcess International to facilitate the sharing of advances and discoveries in the biopharmaceutical sector. InVitria's Director of Cell Culture, Dr. Steve Pettit, will present the performance enhancing features of ZAP-CHO, a new media component for Chinese hamster ovary (CHO) cell culture. Dr. Pettit will present the advantages of this new cell culture supplement at 3:30 pm on Wednesday, May 20 inside the BioProcess Theater.
ZAP-CHO, a new product from InVitria, enhances performance of mammalian cell culture including improved cell growth and antibody production. It achieves these performance advantages in chemically defined media that are completely free of animal components. Previously, the performance seen with ZAP-CHO was only possible by utilizing animal components such as FBS (fetal bovine serum), BSA (bovine serum albumin) or plasma-derived HSA (human serum albumin) in cell culture media.
"Our team of scientists has developed supplements that not only meet the regulatory requirements of researchers using hybridoma and CHO cell culture, but it exceeds their performance expectations as well," said Dr. Pettit. "InVitria products have been utilized by customers to successfully achieve greater cell productivity and growth; faster cell doublings; and improved consistency."
About InVitria (www.InVitria.com) For more information about InVitria's performance enhancing reagents, contact us at This e-mail address is being protected from spambots. You need JavaScript enabled to view it or call 1-800-916-8311.
|
-
Blog: The Cell Culture Dish
Strategies for Improving Viral Yield in Vaccine Manufacturing
A recent article in Pharma Times titled "US biopharma: nearly 300 vaccines in R&D," points out that there are currently 300 vaccines either in clinical studies or under review by the Food and Drug Administration (FDA). While not all vaccines are cell culture derived vaccines, it does indicate that a large number of cell culture based viral vaccines are in the pipeline and that perhaps viral vaccine manufacturing should be examined. One area under consideration is how to improve viral yield so that vaccines can be made at lower cost ... Read More
-
Latest News
InVitria Attends the 13th Bi-Annual Cell Culture Engineering Conference
March 29, 2012 - InVitria is attending the 13th Bi-Annual Cell Culture Engineering Conference in Scottsdale, Arizona April 22nd through the 27th. This event is an invitation only conference that includes approximately 350 of the world's top academic and industry cell culture scientists. Topics at the conference range from fundamental science to the engineering challenges of cell culture process development.... read more
